Sri Ganapathi Drug Intermediates Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 15-12-2024
- Paid Up Capital ₹ 1.25 Cr
as on 15-12-2024
- Company Age 14 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 23.45 Cr
as on 15-12-2024
- Revenue -19.95%
(FY 2020)
- Profit 33.82%
(FY 2020)
- Ebitda 192.63%
(FY 2020)
- Net Worth -0.72%
(FY 2020)
- Total Assets -10.76%
(FY 2020)
About Sri Ganapathi Drug Intermediates
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.25 Cr.
The company currently has active open charges totaling ₹23.45 Cr.
Koti Tatikonda, Venkata Jogi, and Sai Thatikonda serve as directors at the Company.
- CIN/LLPIN
U24232TG2010PTC070402
- Company No.
070402
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Sep 2010
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sri Ganapathi Drug Intermediates?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Koti Tatikonda  | Director | 10-Sep-2010 | Current |
| Venkata Jogi | Additional Director | 30-Mar-2015 | Current |
| Sai Thatikonda | Director | 03-Jul-2023 | Current |
Financial Performance of Sri Ganapathi Drug Intermediates.
Sri Ganapathi Drug Intermediates Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 19.95% decrease. The company also saw a substantial improvement in profitability, with a 33.82% increase in profit. The company's net worth dipped by a decrease of 0.72%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sri Ganapathi Drug Intermediates?
In 2019, Sri Ganapathi Drug Intermediates had a promoter holding of 27.00% and a public holding of 73.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 19 May 2016 | ₹2.25 Cr | Open |
State Bank Of India Creation Date: 18 Apr 2013 | ₹9.00 Cr | Open |
State Bank Of India Creation Date: 18 Mar 2011 | ₹9.00 Cr | Open |
How Many Employees Work at Sri Ganapathi Drug Intermediates?
Unlock and access historical data on people associated with Sri Ganapathi Drug Intermediates, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sri Ganapathi Drug Intermediates, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sri Ganapathi Drug Intermediates's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
